Blown off course, Bluebird shares tick up on positive gene therapy readout

Bluebird bio has presented updated data on its cerebral adrenoleukodystrophy (CALD) gene therapy ahead of a planned filing for FDA approval. Most patients were alive and free from major functional disabilities after 24 weeks of follow-up, suggesting elivaldogene autotemcel stabilizes the disease.